Metachronous non-muscle invasive bladder cancer after UTUC has worse recurrence and progression with BCG than primary disease
Doctors found that bladder cancer returning later has higher risk of coming back again
This systematic review and meta-analysis of 1292 patients found that metachronous non-muscle invasive bladder cancer after upper tract uroth…
A large review shows bladder cancer returning after a previous kidney cancer treatment is more likely to grow back. This group also has a lo…
BCG plus mitomycin did not improve disease-free survival versus BCG alone in high-risk non-muscle-invasive bladder cancer patients
Adding mitomycin to bladder cancer treatment did not improve survival compared to bacillus calmette-guerin alone in this trial
This randomized Phase 3 trial enrolled 501 BCG-naive patients with high-grade pTa or any grade pT1 non-muscle-invasive bladder cancer. The s…
Doctors tested adding mitomycin to standard bladder cancer therapy. Patients receiving both drugs did not live longer without disease than t…
Systematic review and meta-analysis compares intravesical gemcitabine/docetaxel versus BCG for non-muscle-invasive bladder cancer
Gemcitabine and docetaxel show similar recurrence-free survival to BCG for bladder cancer
This systematic review and meta-analysis evaluated intravesical gemcitabine and docetaxel compared with Bacillus Calmette-Guérin (BCG) in pa…
A meta-analysis of 1634 patients found gemcitabine and docetaxel offered recurrence-free survival rates comparable to BCG therapy for non-mu…
Office-based holmium-YAG TULA shows feasibility and safety for recurrent NMIBC in a high-risk cohort
Laser Treatment for Bladder Cancer Now Done in Office
This retrospective cohort study evaluated 53 patients undergoing their first office-based transurethral laser ablation (TULA) for recurrent …
Men with small, recurring bladder tumors can now get laser treatment in an office instead of surgery, avoiding hospital stays and general an…
Adjuvant intravesical BCG versus Epirubicin in intermediate-risk non-muscle invasive bladder cancer
A Common Bladder Cancer Treatment Extends Remission, But at a Cost
This randomized controlled trial compared adjuvant intravesical BCG and Epirubicin in 122 patients with intermediate-risk non-muscle invasiv…
For a common bladder cancer, one treatment keeps the disease away longer, but the other may offer a better daily life.
Audit plus peer comparison improved documentation of tumour features and resection completeness in non-muscle-invasive bladder cancer surgery
Audit and feedback improved documentation of bladder cancer surgery details in a large trial
This cluster randomised controlled trial involved 14,915 patients undergoing transurethral resection of bladder tumour surgery across 201 si…
This large study examined whether adding peer comparison and education to standard audits changed how bladder cancer surgery was performed.
Spinal anesthesia associated with lower recurrence than general anesthesia in non-muscle invasive bladder cancer
Spinal anesthesia linked to lower bladder cancer recurrence rates in single hospital study
A single-center randomized trial of 287 patients with non-muscle invasive bladder cancer found spinal anesthesia was associated with lower 2…
Patients with early-stage bladder cancer had lower recurrence rates when spinal anesthesia was used instead of general anesthesia during tum…
Research across Urologic Neoplasms
Related studies from across the Urologic Neoplasms family.
Neoadjuvant chemoimmunotherapy achieves higher pathological complete response rates than chemotherapy alone in muscle-invasive bladder cancer
Chemoimmunotherapy Shows Higher Response Rates in Bladder Cancer
This network meta-analysis of 2234 patients with muscle-invasive bladder cancer compares neoadjuvant chemoimmunotherapy (NICT), chemotherapy…
A new analysis shows that combining chemotherapy and immunotherapy may lead to higher response rates for patients with muscle-invasive bladd…
Meta-analysis compares bladder preservation therapy vs cystectomy in elderly muscle-invasive bladder cancer
Bladder Preservation May Be Safe for Older Bladder Cancer Patients
This meta-analysis of 4888 elderly patients with muscle-invasive bladder cancer found no significant difference in 1-, 5-, and 10-year overa…
For older adults with aggressive bladder cancer, keeping the bladder may offer survival rates equal to surgery for the first five years, but…
Phase 3 RCT Shows Perioperative Enfortumab Vedotin and Pembrolizumab Benefit Muscle-Invasive Bladder Cancer
New Hope for Bladder Cancer Patients Who Can’t Tolerate Standard Chemo
This phase 3 randomized controlled trial enrolled 344 patients with muscle-invasive bladder cancer ineligible for cisplatin-based chemothera…
A new two-drug treatment more than doubles the odds of staying cancer-free for bladder cancer patients who can't handle standard chemo.
Durvalumab plus chemotherapy improves event-free and overall survival in muscle-invasive bladder cancer compared to chemotherapy alone
New treatment approach improves survival for advanced bladder cancer patients before surgery
This randomized, phase III, open-label trial evaluated neoadjuvant and adjuvant durvalumab combined with gemcitabine and cisplatin versus ge…
Adding an immune drug to standard chemotherapy before bladder surgery helps patients stay cancer-free longer and live longer than older trea…
Neoadjuvant nivolumab alone or with ipilimumab in cisplatin-ineligible muscle-invasive bladder cancer
Hope for Bladder Cancer When Chemo Isn't an Option
This Phase II trial evaluated neoadjuvant nivolumab alone or with ipilimumab in 30 cisplatin-ineligible patients with muscle-invasive bladde…
Patients with advanced bladder cancer who can't take standard chemo may now qualify for surgery after a new immunotherapy treatment.
Phase II trial finds adding gemcitabine to cisplatin-radiotherapy does not improve 2-year disease-free survival in muscle-invasive bladder cancer
Adding gemcitabine to cisplatin did not improve disease-free survival in bladder cancer patients
A Phase II randomized trial in 69 patients with pT2-pT3N0M0 muscle-invasive bladder cancer found similar 2-year disease-free survival (58.3%…
Adding gemcitabine to cisplatin radiotherapy did not improve disease-free survival for bladder cancer patients, with similar two-year rates …
Neoadjuvant sacituzumab govitecan plus pembrolizumab shows 39% clinical complete response in MIBC
Drug combination shows promise for bladder cancer patients who cannot take standard chemotherapy
A single-arm phase 2 study of 49 patients with muscle-invasive bladder cancer ineligible for cisplatin found a clinical complete response ra…
A new drug combination helped 39% of bladder cancer patients who couldn't take standard chemotherapy achieve a complete response before surg…
Questions about Non-Muscle Invasive Bladder Cancer
What are the differences between BCG alone and BCG plus mitomycin for high-risk non-muscle invasive bladder cancer?
For high-risk NMIBC, BCG plus mitomycin does not improve disease-free survival compared to BCG alone, and may increase toxicity.
Full answer →Is adjuvant BCG better than Epirubicin for intermediate-risk non-muscle invasive bladder cancer patients?
For intermediate-risk NMIBC, BCG and epirubicin show comparable recurrence and progression rates, but BCG may provide a longer time to recurrence.
Full answer →How does intravesical gemcitabine or docetaxel compare to BCG for non-muscle invasive bladder cancer?
Intravesical gemcitabine/docetaxel may offer similar or better recurrence-free survival with fewer side effects compared to BCG for non-muscle invasive bladder cancer, but evidence is still emerging.
Full answer →Does adding mitomycin to BCG improve disease-free survival for high-risk non-muscle invasive bladder cancer?
Adding mitomycin to BCG does not improve disease-free survival for high-risk non-muscle invasive bladder cancer compared to BCG alone.
Full answer →